Antidepressants are one of the most widely prescribed drugs in England. In 2018, over 70-million antidepressant prescriptions were dispensed. The striking rise in prescribing (nearly doubling in a decade) is due mainly to long-term treatment rather than increased diagnosis. However, little is known about the health consequences of long-term use of these medicines.
Researchers from Bristol’s Centre for Academic Mental Health aimed to find out if long-term antidepressant use (over five and ten years) was associated with the onset of six health problems: diabetes, high blood pressure, coronary heart disease, stroke and related syndromes, and two mortality outcomes (death from cardiovascular disease and from any cause).
Using data from UK Biobank, a large-scale biomedical database and research resource containing anonymized genetic, lifestyle and health information from half a million UK participants, the team linked comprehensive health data with prescription and disease data (using GP records) on 222,121 adults aged between 40 to 69-years old.
They compared the risk of developing adverse health outcomes between those who had not taken antidepressants and those who had been treated with the most commonly prescribed antidepressants in England over ten years. These were categorized by drug class as selective serotonin reuptake inhibitors often known as SSRIs, called citalopram, sertraline, fluoxetine and paroxetine and ‘other’ non-SSRI antidepressants called mirtazapine, venlafaxine, duloxetine and trazodone.
The researchers found that, once pre-existing risk factors had been taken into account, long-term antidepressant use was associated with an increased risk of coronary heart disease, and an increased risk of death from cardiovascular disease and from any cause. The risks were greater for non-SSRI antidepressants (mirtazapine, venlafaxine, duloxetine, trazodone), with the use of such drugs associated with a two-fold increased risk of coronary heart disease, cardiovascular mortality, and all-cause mortality at ten years.
There was also some evidence that antidepressants, and particularly SSRI’s, were associated with a reduced risk (23 to 32 per cent lower risk) of developing high blood pressure and diabetes. The reasons for these apparently paradoxical findings are unclear and further work is needed to understand the extent to which differences are due to severity of the underlying depression or due to the way the different drugs work.
Dr Narinder Bansal, the study’s lead author and Honorary Research Fellow at Bristol’s Centre for Academic Mental Health and Centre for Academic Primary Care, said: “While we have taken into account a wide range of pre-existing risk factors for cardiovascular disease, including those that are linked to depression such as excess weight, smoking, and low physical activity, it is difficult to fully control for the effects of depression in this kind of study, partly because there is considerable variability in the recording of depression severity in primary care.
“This is important because many people taking antidepressants such as mirtazapine, venlafaxine, duloxetine and trazodone may have a more severe depression. This makes it difficult to fully separate the effects of depression from the effects of medication. Further research is needed to assess whether the associations we have seen are genuinely due to the drugs, and if so, why this might be.
“Meanwhile, our message for clinicians is that prescribing antidepressants in the long term may not be harm-free. We hope that this study will help doctors and patients have more informed conversations when weighing up the potential risks and benefits of treatments for depression. Regardless of whether the drugs are the underlying cause of these problems, our findings emphasize the importance of proactive cardiovascular monitoring and prevention in patients who have depression and are on antidepressants given that both have been associated with higher risks.
“For anyone with any concerns about their long-term use of antidepressants, we urge them to talk to their GP first before they stop taking the medication. It is very important they do not stop taking them suddenly.”
The study was funded by the National Institute of Health and Care (NIHR) Research School for Primary Care Research (NIHR SPCR) and was also supported by the National Institute of Health and Care (NIHR) Bristol Biomedical Research Centre (NIHR Bristol BRC) a partnership between University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol.
‘Antidepressant use and risk of adverse outcomes: a population-based cohort study’ by Narinder Bansalet al. in the British Journal of Psychiatry
Source/Credit: University of Bristol